Valuation : Curis, Inc.

Market Cap 2.82M 2.43M 2.28M 2.08M 3.89M 267M 3.91M 27.04M 10.46M 137M 10.6M 10.36M 435M P/E 2026 *
-0.06x
P/E 2027 * -0.19x
Enterprise Value 2.82M 2.43M 2.28M 2.08M 3.89M 267M 3.91M 27.04M 10.46M 137M 10.6M 10.36M 435M EV / Sales 2026 *
-
EV / Sales 2027 * 0.31x
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Curis, Inc.

1 day-4.07%
1 week-8.45%
Current month-12.75%
1 month-64.48%
3 months-86.17%
6 months-93.69%
Current year-93.42%
1 week 1.28
Extreme 1.276
1.48
1 month 1.28
Extreme 1.276
4.15
Current year 1.28
Extreme 1.276
24.2
1 year 1.28
Extreme 1.276
39
3 years 1.28
Extreme 1.276
349.8
5 years 1.28
Extreme 1.276
3,492
10 years 1.28
Extreme 1.276
7,440
Manager TitleAgeSince
Chief Executive Officer 59 2018-09-23
Director of Finance/CFO 54 2022-08-04
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 73 2003-10-31
Chairman 84 2017-05-15
Director/Board Member 71 2010-06-02
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Free

Chief Executive Officer

110,090 0.2824%
7/7/26 Free

Director

6,800 0.0174%
7/7/26 Free

Chairman

6,800 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-4.07%-8.45%-96.20%-99.38% 2.82M
-0.82%-3.77%-2.49%+14.92% 48.41B
+0.35%+0.77%+415.08%+558.44% 45.01B
-1.46%+2.20%+40.68%+23.65% 44.07B
-2.80%-2.69%+0.74%+81.18% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.75%+3.06% - - 17.77B
-0.02%+1.42%+20.20%+118.17% 16.5B
-0.56%-0.50%+11.39%+31.41% 14.45B
-1.95%+0.57%+75.28%+42.16% 13.77B
Average -1.31%-0.76%+53.16%+90.44% 27.39B
Weighted average by Cap. -1.03%-0.12%+87.36%+135.21%

Financials

2026 *2027 *
Net sales - 9.25M 7.95M 7.48M 6.83M 12.74M 877M 12.81M 88.65M 34.3M 448M 34.73M 33.98M 1.43B
Net income -52.02M -44.73M -42.08M -38.4M -71.66M -4.93B -72.03M -499M -193M -2.52B -195M -191M -8.02B -45.23M -38.89M -36.59M -33.39M -62.31M -4.29B -62.63M -433M -168M -2.19B -170M -166M -6.97B
Net Debt - -
Logo Curis, Inc.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Employees
22
Date Price Change Volume
26-09-08 US$1.300 -3.70% 62,124
26-09-04 US$1.350 -1.46% 96,907
26-09-03 US$1.370 -0.72% 126,042
26-09-02 US$1.380 -2.82% 85,272
26-09-01 US$1.420 -4.70% 65,423
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.350USD
Average target price
42.67USD
Spread / Average Target
+3,060.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRIS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!